Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc., and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism, and workforce diversity.
NIH, in a recent notice, prohibits grant recipients from operating programs that promote DEI or “discriminatory equity ideology,” or engage in “discriminatory prohibited boycott.”
